
## **Constantinos O'Mahony**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/924246/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Non-invasive characterization of pleural and pericardial effusions using T1 mapping by magnetic resonance imaging. European Heart Journal Cardiovascular Imaging, 2022, 23, 1117-1126.	1.2	8
2	An Observational Study Assessing the Predictors of Procedural Failure From the Radial Approach: Is Right Radial Access Always the Best?. Cardiovascular Revascularization Medicine, 2022, 42, 86-91.	0.8	2
3	Diagnostic Impact of Repeated Expert Review & Longâ€Term Followâ€Up in Determining Etiology of Idiopathic Cardiac Arrest. Journal of the American Heart Association, 2021, 10, e019610.	3.7	7
4	Is This the Prime Time for Transradial Access Left Ventricular Endomyocardial Biopsy?. Interventional Cardiology Review, 2021, 16, e29.	1.6	0
5	Complete Versus Culprit only Revascularisation in Patients with Cardiogenic Shock Complicating Acute Myocardial Infarction: Incidence and Outcomes from the London Heart Attack Group. Cardiovascular Revascularization Medicine, 2020, 21, 350-358.	0.8	5
6	Mortality Among Referral Patients With Hypertrophic Cardiomyopathy vs the General European Population. JAMA Cardiology, 2020, 5, 73.	6.1	69
7	latrogenic catheterâ€induced ostial coronary artery dissections: Prevalence, management, and mortality from a cohort of 55,968 patients over 10 years. Catheterization and Cardiovascular Interventions, 2020, 98, 649-655.	1.7	14
8	The price and value of implantable cardioverter defibrillators in hypertrophic cardiomyopathy. International Journal of Cardiology, 2020, 311, 52-53.	1.7	0
9	Routine aspiration thrombectomy is associated with increased stroke rates during primary percutaneous coronary intervention for myocardial infarction. American Journal of Cardiovascular Disease, 2020, 10, 548-556.	0.5	0
10	The Safety and Feasibility of Transitioning From Transfemoral to Transradial Access Left Ventricular Endomyocardial Biopsy. Journal of Invasive Cardiology, 2020, 32, E349-E354.	0.4	2
11	Effectiveness of the 2014 European Society of Cardiology guideline on sudden cardiac death in hypertrophic cardiomyopathy: a systematic review and meta-analysis. Heart, 2019, 105, heartjnl-2018-313700.	2.9	31
12	Development of a Novel Risk Prediction Model for Sudden Cardiac Death in Childhood Hypertrophic Cardiomyopathy (HCM Risk-Kids). JAMA Cardiology, 2019, 4, 918.	6.1	147
13	Routine use of fluoroscopic guidance and up-front femoral angiography results in reduced femoral complications in patients undergoing coronary angiographic procedures: an observational study using an Interrupted Time-Series analysis. Heart and Vessels, 2019, 34, 419-426.	1.2	3
14	International External Validation Study of the 2014 European Society of Cardiology Guidelines on Sudden Cardiac Death Prevention in Hypertrophic Cardiomyopathy (EVIDENCE-HCM). Circulation, 2018, 137, 1015-1023.	1.6	149
15	Ineffective and prolonged apical contraction is associated with chest pain and ischaemia in apical hypertrophic cardiomyopathy. International Journal of Cardiology, 2018, 251, 65-70.	1.7	15
16	Longâ€ŧerm outcomes for different surgical strategies to treat left ventricular outflow tract obstruction in hypertrophic cardiomyopathy. European Journal of Heart Failure, 2018, 20, 398-405.	7.1	16
17	Contemporary trends in cardiogenic shock: Incidence, intra-aortic balloon pump utilisation and outcomes from the London Heart Attack Group. European Heart Journal: Acute Cardiovascular Care, 2018, 7, 16-27.	1.0	96
18	Doppler echocardiography underestimates the prevalence and magnitude of mid avity obstruction in patients with symptomatic hypertrophic cardiomyopathy. Catheterization and Cardiovascular Interventions, 2018, 91, 783-789.	1.7	9

#	Article	IF	CITATIONS
19	Complete Versus Culprit-Only Lesion Intervention in Patients With AcuteÂCoronary Syndromes. Journal of the American College of Cardiology, 2018, 72, 1989-1999.	2.8	95
20	Coronary artery dissection in the puerperium: A case report and literature review. Obstetric Medicine, 2018, 11, 144-147.	1.1	3
21	Angiography Alone Versus AngiographyÂPlus Optical CoherenceÂTomography toÂGuide PercutaneousÂCoronaryÂIntervention. JACC: Cardiovascular Interventions, 2018, 11, 1313-1321.	2.9	103
22	Identifying unmet clinical need in hypertrophic cardiomyopathy using national electronic health records. PLoS ONE, 2018, 13, e0191214.	2.5	27
23	Predictors of atrial fibrillation in hypertrophic cardiomyopathy. Heart, 2017, 103, 672-678.	2.9	71
24	Affairs of the heart: outcomes in men and women with hypertrophic cardiomyopathy. European Heart Journal, 2017, 38, 3441-3433.	2.2	6
25	Prevalence and outcomes of coronary artery perforation during percutaneous coronary intervention. EuroIntervention, 2017, 13, e595-e601.	3.2	48
26	Intracoronary ethanol ablation of ventricular premature contractions in patients with preserved left ventricular function. Indian Pacing and Electrophysiology Journal, 2016, 16, 165-168.	0.6	1
27	Inverted U-Shaped Relation Between the Risk of Sudden Cardiac Death and Maximal Left Ventricular Wall Thickness in Hypertrophic Cardiomyopathy. Circulation: Arrhythmia and Electrophysiology, 2016, 9, .	4.8	19
28	Prediction of thromboâ€embolic risk in patients with hypertrophic cardiomyopathy ( <scp>HCM</scp> ) Tj ETQq0	0 0 rgBT / 7.1	Overlock 10
29	Clinical and genetic predictors of major cardiac events in patients with Anderson–Fabry Disease. Heart, 2015, 101, 961-966.	2.9	78
30	Novel genotype–phenotype associations demonstrated by high-throughput sequencing in patients with hypertrophic cardiomyopathy. Heart, 2015, 101, 294-301.	2.9	124
31	A clinical update on the use of resolute stents with dual anti-platelet therapy interruption. Interventional Cardiology, 2014, 6, 453-462.	0.0	0
32	Prevention of sudden cardiac death in hypertrophic cardiomyopathy. Heart, 2014, 100, 254-260.	2.9	34
33	2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. European Heart Journal, 2014, 35, 2733-2779.	2.2	3,469
34	A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM) Tj ETQq0 (	) 0 <sub>.rg</sub> BT /C	verlock 10 T
35	Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: systematic review. Heart, 2014, 100, 465-472.	2.9	248

36	Role of Serum N-Terminal Pro-Brain Natriuretic Peptide Measurement in Diagnosis of Cardiac Involvement in Patients With Anderson-Fabry Disease. American Journal of Cardiology, 2013, 111, 111-117.	1.6	54

#	Article	IF	CITATIONS
37	A validation study of the 2003 American College of Cardiology/European Society of Cardiology and 2011 American College of Cardiology Foundation/American Heart Association risk stratification and treatment algorithms for sudden cardiac death in patients with hypertrophic cardiomyopathy. Heart, 2013, 99, 534-541.	2.9	127
38	Relation between serum N-terminal pro-brain natriuretic peptide and prognosis in patients with hypertrophic cardiomyopathy. European Heart Journal, 2013, 34, 2529-2537.	2.2	84
39	Sudden Cardiac Death in Hypertrophic Cardiomyopathy. Circulation: Arrhythmia and Electrophysiology, 2013, 6, 443-451.	4.8	72
40	The relation of ventricular arrhythmia electrophysiological characteristics to cardiac phenotype and circadian patterns in hypertrophic cardiomyopathy. Europace, 2012, 14, 724-733.	1.7	45
41	The long-term survival and the risks and benefits of implantable cardioverter defibrillators in patients with hypertrophic cardiomyopathy. Heart, 2012, 98, 116-125.	2.9	146
42	Exercise-Induced Left Ventricular Outflow Tract Obstruction in Symptomatic Patients With Anderson-Fabry Disease. Journal of the American College of Cardiology, 2011, 58, 88-89.	2.8	34
43	The ECG in arrhythmogenic right ventricular cardiomyopathy: Â-waves and anterior T-wave inversion. BMJ Case Reports, 2011, 2011, bcr0920103318-bcr0920103318.	0.5	0
44	Incidence and predictors of anti-bradycardia pacing in patients with Anderson-Fabry disease. Europace, 2011, 13, 1781-1788.	1.7	63
45	Anderson-Fabry Disease and the Heart. Progress in Cardiovascular Diseases, 2010, 52, 326-335.	3.1	83
46	Prevalence of Desmosomal Protein Gene Mutations in Patients With Dilated Cardiomyopathy. Circulation: Cardiovascular Genetics, 2010, 3, 314-322.	5.1	145
47	Cardiac involvement in Anderson-Fabry disease. BMJ Case Reports, 2010, 2010, bcr0220102760-bcr0220102760.	0.5	0
48	The quest for perfection: the contribution of the electrocardiogram to the prevention of sudden death in hypertrophic cardiomyopathy. Europace, 2009, 11, 548-549.	1.7	0